Symptom severity scale of the DSM5 for schizophrenia, and other psychotic disorders: diagnostic validity and clinical feasibility
Introduction
Numerous studies in the last century have increasingly emphasized that the boundaries between nosological entities may not be categorical, and putative comorbidity of various disorders may reflect impairments in common clinical dimensions, genetic variation, human behavior and neurobiological functions (e.g., Peralta and Cuesta, 2007, Owen et al., 2007, Ritsner and Gottesman, 2011). The categorical approach defines subgroups within the disorder, whereas the dimensional approach emphasizes the severity of different symptom clusters. As such, it is important to explicitly include dimensional assessments of the core symptoms of psychotic disorders in order to identify pertinent variability. Therefore, the most useful current approach for the classification of schizophrenia (SZ), other psychotic (OP), and mood disorders may be the complementary use of categorical and dimensional representations of functional psychoses (Salokangas, 2003, Brown and Barlow, 2005, Dikeos et al., 2006, Dutta et al., 2007, Helzer et al., 2008, van Os, 2009, Kamphuis and Noordhof, 2009).
Recently, the American Psychiatric Association (APA) posted a draft of the Diagnostic and Statistical Manual of Mental Disorders, 5th ed. (DSM5) on a special web site, www.dsm5.org. One of innovations in the DSM5 is the extensive use of so-called dimensional assessments to account for severity of symptoms of schizophrenia and other psychotic disorders. In particular, the DSM5 Workgroup suggests that each of the diagnostic symptoms for these disorders (‘Criterion A’) may be rated using a new symptom severity scale that we called the Symptom Severity Scale DSM5 (SS-DSM5) in the current study (http://www.dsm5.org/Pages/Default.aspx)1.
The psychometric properties of the SS-DSM5 in terms of reliability, and validity have not been presented. The purpose of our study therefore was to establish the psychometric properties (factor structure, reliability, internal consistency, convergent and diagnostic ability) of the SS-DSM5 scale in an unselected sample of patients with psychotic (SZ/OP) and mood disorders that were receiving standard care in inpatient and out-patient settings of a large university hospital.
Section snippets
Methods
In this study, we used a cross-sectional design enrolling an unselected convenience sample of inpatients and outpatients with SZ/OP and mood disorders who received standard care from February 2010 to March 2011 in the routine clinical practice settings at Shaar Menashe Mental Health Center affiliated to the Rappaport Faculty of Medicine, Technion, Israel. The study included men and women ages 18–80 years. The design adhered to the Declaration of Helsinki and ICH/Good Clinical Practice
Factor structure
Results from an exploratory factor analysis of SS-DSM5 dimensions are summarized in Table 1. We found a model with two latent factors (scales), which were labeled as ‘Psychotic’ and ‘Deficit’ scales. The first factor included negative loadings of delusions, disorganization, abnormal psychomotor behavior and mania scores. The second factor was constructed using restricted emotional expression, avolition and impaired cognition scores with negative loadings. Correspondingly, they accounted for
Discussion
This study aimed to establish the psychometric properties and diagnostic validity of the SS-DSM5 scale for dimensional diagnosis of SZ/OP disorders.
The key psychometric properties of the SS-DSM5 scale are:
- (i)
The factorial analysis demonstrates a two-factorial structure of the SS-DSM5 dimensions, which were labeled ‘psychotic’, and ‘deficit’ scales, respectively.
- (ii)
The reliability and internal consistency of the SS-DSM5 total score and its scales were shown to be strong. Cronbach's alpha was >0.70 for
Authors' contributions
RMS originated the study design. RMS and AG were responsible for collection of data, statistical analysis, and an interpretation of data and drafted the manuscript. MM and MA participated in acquisition of data and interpretation of data. All authors have given final approval of the version to be published.
Acknowledgments
The authors especially thank R. Kurs, B.A. for editing this manuscript.
References (29)
- et al.
Mania Rating Scale: scale construction and inter-observer agreement
Neuropharmacology
(1978) - et al.
Dimensions and the psychosis phenotype
International Journal of Methods Psychiatric Research
(2007) The Bech-Rafaelsen Mania Scale in clinical trials of therapies for bipolar disorder: a 20-year review of its use as an outcome measure
CNS Drugs
(2002)- et al.
Dimensional versus categorical classification of mental disorders in the fifth edition of the diagnostic and statistical manual of mental disorders and beyond: comment on the special section
Journal of Abnormal Psychology
(2005) - Diagnostic and Statistical Manual of Mental Disorders, 5th ed. Available from: (DSM-5) web sites, http://www.dsm5.org....
- et al.
Distribution of symptom dimensions across Kraepelinian divisions
British Journal of Psychiatry
(2006) - et al.
Biological, life course, and cross-cultural studies all point toward the value of dimensional and developmental ratings in the classification of psychosis
Schizophrenia Bulletin
(2007) - et al.
The role of the affective and cognitive bases of attitudes insusceptibility to affectively and cognitively based persuasion
Personality and Social Psychology Bulletin
(1999) Whither DSM-V?
The British Journal of Psychiatry
(2009)Neuroleptic equivalence
The Pharmaceutical Journal
(1989)
ECDU Assessment Manual for Psychopharmacology
A dimensional option for the diagnosis of substance dependence in DSM-V
International Journal of Methods in Psychiatric Research
Dimensional Approaches in Diagnostic Classification: Refining the Research Agenda for DSM-V
Cited by (12)
The factor structure and clinical utility of clinician-rated dimensions of psychosis symptom severity in patients with recent-onset psychosis: Results of a 1-year longitudinal follow-up prospective cohort study
2022, Psychiatry ResearchCitation Excerpt :The CRDPSS is an 8-item scale administered by the clinician during patient evaluation (Heckers et al., 2013); it is considered helpful for establishing a treatment plan and determining the prognosis, and facilitates research on pathophysiology (Allardyce et al., 2007; Heckers, 2008). In a previous study, Ritsner et al. (2013) showed that CRDPSS scale eased the assessment, and the agreement of the diagnostic decisions between the CRDPSS and PANSS was substantial for all psychotic disorders. Several attempts to determine the factor structure of the CRDPSS have been made, and yielded psychotic and deficit scales (Ritsner et al., 2013), positive/speech symptoms, negative/cognition, and depression/mania scales (Park et al., 2016), and deficit/motor symptoms, positive symptoms, and mood symptoms scales (Berendsen et al., 2020).
Psychometric properties of the DSM-5 Clinician-Rated Dimensions of Psychosis Symptom Severity
2020, Schizophrenia ResearchCitation Excerpt :These results some evidence for convergent validity of the CRDPSS. This is in line with previous studies of Ritsner et al. (2013) and Park et al. (2016), reporting an adequate convergent validity of the CRDPSS. In addition, we found significant higher severity scores of the CRDPSS in the SSD group, which supports diagnostic validity of the CRDPSS.
Gesture impairments in schizophrenia are linked to increased movement and prolonged motor planning and execution
2018, Schizophrenia ResearchCitation Excerpt :Patients were interviewed with the Comprehensive Assessment of Symptoms and History (CASH) (Andreasen et al. 1992). Current symptom severity was assessed with the severity scale of the DSM 5 for schizophrenia (Ritsner et al. 2013) and the Positive and Negative Syndrome Scale (PANSS) (Kay et al. 1987). Between group differences in demographic and clinical characteristics were analyzed with Mann-Whitney-U tests.
Insulin-like Growth Factor 2 (IGF-2) and Insulin-like Growth Factor Binding Protein 7 (IGFBP-7) Are Upregulated after Atypical Antipsychotics in Spanish Schizophrenia Patients
2022, International Journal of Molecular Sciences